CN115894271A - A kind of preparation method of the paracetamol that controls paracetamol impurity H content - Google Patents
A kind of preparation method of the paracetamol that controls paracetamol impurity H content Download PDFInfo
- Publication number
- CN115894271A CN115894271A CN202211497629.2A CN202211497629A CN115894271A CN 115894271 A CN115894271 A CN 115894271A CN 202211497629 A CN202211497629 A CN 202211497629A CN 115894271 A CN115894271 A CN 115894271A
- Authority
- CN
- China
- Prior art keywords
- paracetamol
- impurity
- preparation
- content
- acetaminophen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 144
- 229960005489 paracetamol Drugs 0.000 title claims abstract description 101
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- UJAOSPFULOFZRR-UHFFFAOYSA-N (4-acetamidophenyl) acetate Chemical compound CC(=O)NC1=CC=C(OC(C)=O)C=C1 UJAOSPFULOFZRR-UHFFFAOYSA-N 0.000 title claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 69
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000002253 acid Substances 0.000 claims abstract description 36
- 229960000583 acetic acid Drugs 0.000 claims abstract description 28
- 238000005917 acylation reaction Methods 0.000 claims abstract description 28
- OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 15
- 230000010933 acylation Effects 0.000 claims abstract description 13
- 239000012452 mother liquor Substances 0.000 claims abstract description 13
- 239000012043 crude product Substances 0.000 claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 11
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- 238000005065 mining Methods 0.000 claims abstract description 7
- 239000007787 solid Substances 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical group [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 12
- 229940001584 sodium metabisulfite Drugs 0.000 claims description 12
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 12
- 238000001953 recrystallisation Methods 0.000 claims description 10
- 238000004042 decolorization Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000002425 crystallisation Methods 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- HLBLWEWZXPIGSM-UHFFFAOYSA-N 4-Aminophenyl ether Chemical compound C1=CC(N)=CC=C1OC1=CC=C(N)C=C1 HLBLWEWZXPIGSM-UHFFFAOYSA-N 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 239000012535 impurity Substances 0.000 abstract description 79
- 239000000047 product Substances 0.000 abstract description 22
- 230000008569 process Effects 0.000 abstract description 11
- 230000002411 adverse Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 239000012467 final product Substances 0.000 abstract description 3
- 238000005886 esterification reaction Methods 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 1
- GGUOCFNAWIODMF-UHFFFAOYSA-N 4-chloroacetanilide Chemical compound CC(=O)NC1=CC=C(Cl)C=C1 GGUOCFNAWIODMF-UHFFFAOYSA-N 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000008213 purified water Substances 0.000 description 4
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003712 decolorant Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- BUGCHAIWUSBYIZ-UHFFFAOYSA-N n-[4-(4-acetamidophenoxy)phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1OC1=CC=C(NC(C)=O)C=C1 BUGCHAIWUSBYIZ-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明属于对乙酰氨基酚杂质去除技术领域,具体涉及一种控制对乙酰氨基酚杂质H含量的对乙酰氨基酚的制备方法。本发明的制备方法,包括以下步骤:将对氨基苯酚、冰醋酸、抗氧化剂及稀酸混合后进行酰化反应,反应后进行采酸、降温结晶、离心,得到固体物质和酰化母液,固体物质经洗涤后得到对乙酰氨基酚粗品;将对乙酰氨基酚粗品依次进行脱色处理、过滤处理、重结晶处理、离心处理、干燥处理,得到对乙酰氨基酚精品;稀酸中醋酸的质量分数为40‑45%。本发明通过降低酰化母液中醋酸浓度来减少对乙酰氨基酚与冰醋酸的酯化反应,从而降低对乙酰氨基酚中杂质H含量。另外,此工艺调整并未对其他杂质的去除和最终产品收率产生明显不利影响。The invention belongs to the technical field of paracetamol impurity removal, and in particular relates to a preparation method of paracetamol for controlling the H content of the paracetamol impurity. The preparation method of the present invention comprises the following steps: carry out acylation reaction after mixing p-aminophenol, glacial acetic acid, antioxidant and dilute acid, carry out acid mining after the reaction, cool down and crystallize, and centrifuge to obtain solid matter and acylation mother liquor, solid After the substance is washed, the crude product of paracetamol is obtained; the crude product of paracetamol is decolorized, filtered, recrystallized, centrifuged, and dried in sequence to obtain the fine product of paracetamol; the mass fraction of acetic acid in dilute acid is 40‑45%. The invention reduces the esterification reaction between acetaminophen and glacial acetic acid by reducing the concentration of acetic acid in the acylation mother liquor, thereby reducing the content of impurity H in the acetaminophen. In addition, this process adjustment did not have a significant adverse effect on the removal of other impurities and the yield of the final product.
Description
技术领域technical field
本发明属于对乙酰氨基酚杂质去除技术领域,具体涉及一种控制对乙酰氨基酚杂质H含量的对乙酰氨基酚的制备方法,即提供一种降低对乙酰氨基酚中对乙酰氨基酚杂质H的方法。The invention belongs to the technical field of acetaminophen impurity removal, and in particular relates to a preparation method of acetaminophen for controlling the content of acetaminophen impurity H, that is, to provide a method for reducing acetaminophen impurity H in acetaminophen method.
背景技术Background technique
对乙酰氨基酚是对氨基苯酚和冰醋酸通过酰化反应生产而成,又名扑热息痛。为白色结晶或结晶性粉末;无臭、味微苦。是一种常用的解热镇痛药,其解热作用缓慢而持久,具有刺激性小、极少有过敏反应等优点。目前对乙酰氨基酚已成为全世界应用最广泛的药物之一,是国际医药市场上头号解热镇痛药,同时也是我国原料药中产量最大的品种之一。Acetaminophen is produced by the acylation reaction of p-aminophenol and glacial acetic acid, also known as paracetamol. It is white crystal or crystalline powder; odorless, slightly bitter taste. It is a commonly used antipyretic and analgesic drug. Its antipyretic effect is slow and long-lasting, and it has the advantages of little irritation and few allergic reactions. At present, acetaminophen has become one of the most widely used drugs in the world. It is the number one antipyretic and analgesic drug in the international pharmaceutical market, and it is also one of the varieties with the largest output of raw materials in my country.
对乙酰氨基酚是对氨基苯酚和冰醋酸通过酰化反应生产而成的,在生产过程中经常会有成品在进入欧盟市场的时候,应符合欧洲药典EP的质量要求,4-乙酰氧基乙酰苯胺这种杂质已经被欧洲药典收录,定义为对乙酰氨基酚杂质H,规定其在对乙酰氨基酚中的含量≤0.05%。Acetaminophen is produced by the acylation reaction of p-aminophenol and glacial acetic acid. During the production process, there are often finished products that should meet the quality requirements of the European Pharmacopoeia EP when they enter the EU market. 4-Acetoxyacetyl The impurity aniline has been included in the European Pharmacopoeia, and it is defined as acetaminophen impurity H, and its content in acetaminophen is regulated to be ≤0.05%.
因此,为了获得合格或更优质的对乙酰氨基酚产品,提高大规模生产过程中不同批次产品的合格率,需要不断研究在制备或纯化对乙酰氨基酚的过程中如何降低对乙酰氨基酚杂质H的含量,提供一种杂质H含量超低的对乙酰氨基酚的制备方法显得尤为重要。Therefore, in order to obtain qualified or better quality acetaminophen products and improve the qualification rate of different batches of products in the large-scale production process, it is necessary to continuously study how to reduce acetaminophen impurities in the process of preparing or purifying acetaminophen H content, it is particularly important to provide a method for preparing acetaminophen with ultra-low impurity H content.
发明内容Contents of the invention
本发明提供一种控制对乙酰氨基酚杂质H含量的对乙酰氨基酚的制备方法,其目的是为了解决现有技术中,合成对乙酰氨基酚过程中产生对乙酰氨基酚杂质H的情况,从而提高对乙酰氨基酚成品的质量,提高不同批次的产品合格率。The present invention provides a kind of preparation method of the paracetamol that controls paracetamol impurity H content, and its purpose is in order to solve the situation in the prior art, produces paracetamol impurity H in the process of synthesizing paracetamol, thereby Improve the quality of acetaminophen finished products and improve the qualified rate of different batches of products.
针对上述技术缺陷,本发明的目的之一是提供控制对乙酰氨基酚杂质H含量的对乙酰氨基酚的制备方法。For above-mentioned technical defect, one of purpose of the present invention is to provide the preparation method of the paracetamol of controlling paracetamol impurity H content.
第一方面,本发明提供一种控制对乙酰氨基酚杂质H含量的对乙酰氨基酚的制备方法,包括以下步骤:First aspect, the present invention provides a kind of preparation method of the paracetamol that controls paracetamol impurity H content, comprises the following steps:
制备对乙酰氨基酚粗品:将对氨基苯酚、冰醋酸、抗氧化剂及稀酸混合后进行酰化反应,反应后进行采酸、降温结晶、离心,得到固体物质和酰化母液,所述固体物质经洗涤后得到对乙酰氨基酚粗品;Preparation of crude paracetamol: p-aminophenol, glacial acetic acid, antioxidant and dilute acid are mixed for acylation reaction, after the reaction, acid mining, cooling crystallization, and centrifugation are carried out to obtain solid matter and acylation mother liquor, the solid matter Obtain paracetamol crude product after washing;
制备对乙酰氨基酚精品:将所述对乙酰氨基酚粗品依次进行脱色处理、过滤处理、重结晶处理、离心处理、干燥处理,得到对乙酰氨基酚精品;Preparing the refined paracetamol: decolorizing, filtering, recrystallizing, centrifuging, and drying the crude paracetamol in sequence to obtain the refined paracetamol;
其中,所述稀酸为冰醋酸水溶液或者之前回收的酰化母液,所述稀酸中醋酸的质量分数为40-45%(例如:41%、43%、44%)。Wherein, the dilute acid is an aqueous solution of glacial acetic acid or the previously recovered acylation mother liquor, and the mass fraction of acetic acid in the dilute acid is 40-45% (for example: 41%, 43%, 44%).
在上述制备方法中,作为一种优选实施方式,所述对氨基苯酚和冰醋酸的摩尔比为1:(1-1.2);In the above preparation method, as a preferred embodiment, the molar ratio of p-aminophenol and glacial acetic acid is 1: (1-1.2);
和/或,所述对氨基苯酚和抗氧化剂的质量比为1:(0.005-0.03),优选为1:(0.015-0.03);And/or, the mass ratio of the p-aminophenol and the antioxidant is 1:(0.005-0.03), preferably 1:(0.015-0.03);
和/或,所述对氨基苯酚和稀酸的质量比为1:(1-3),优选为1:(1.4-1.6)。And/or, the mass ratio of p-aminophenol and dilute acid is 1:(1-3), preferably 1:(1.4-1.6).
在上述制备方法,作为一种优选的实施方式,所述对氨基苯酚含量≥99.7%(HPLC),对氨基苯酚中的4,4'-二氨基二苯醚含量≤0.1%(HPLC)。In the above preparation method, as a preferred embodiment, the content of p-aminophenol is ≥99.7% (HPLC), and the content of 4,4'-diaminodiphenyl ether in p-aminophenol is ≤0.1% (HPLC).
在上述制备方法,作为一种优选实施方式,所述酰化反应的时间为3-6h(例如:4h、5h);In the above preparation method, as a preferred embodiment, the time of the acylation reaction is 3-6h (for example: 4h, 5h);
所述酰化反应的温度为95-120℃(例如:100℃、105℃、110℃、115℃);优选为95℃-98℃。The temperature of the acylation reaction is 95-120°C (for example: 100°C, 105°C, 110°C, 115°C); preferably 95°C-98°C.
在上述制备方法,作为一种优选实施方式,所述采酸的温度为100-150℃(例如:120℃、130℃、140℃);In the above preparation method, as a preferred embodiment, the temperature of the acid extraction is 100-150°C (for example: 120°C, 130°C, 140°C);
所述采酸的时间为2-3h(例如2.5h);The time for the acid extraction is 2-3h (for example 2.5h);
待对氨基苯酚和采出醋酸的质量比为1:(0.16-0.30)时,停止采酸。When the mass ratio of p-aminophenol and extracted acetic acid is 1: (0.16-0.30), stop acid extraction.
在上述制备方法,作为一种优选实施方式,所述降温结晶是指降温至25-30℃结晶。In the above preparation method, as a preferred embodiment, the temperature-lowering crystallization refers to cooling to 25-30° C. for crystallization.
在上述制备方法,作为一种优选实施方式,在所述脱色处理中,向所述对乙酰氨基酚粗品中加入纯水、脱色剂和抗氧化剂进行脱色处理;In the above preparation method, as a preferred embodiment, in the decolorization treatment, pure water, a decolorant and an antioxidant are added to the crude acetaminophen to perform decolorization treatment;
进一步优选地,所述对乙酰氨基酚粗品、纯水、脱色剂和抗氧化剂的质量比为1:(1.5-2.0):(0.02-0.07):(0.01-0.05);Further preferably, the mass ratio of the paracetamol crude product, pure water, decolorizer and antioxidant is 1:(1.5-2.0):(0.02-0.07):(0.01-0.05);
和/或,所述脱色剂为活性炭;And/or, the decolorizing agent is activated carbon;
和/或,所述抗氧化剂为焦亚硫酸钠;And/or, the antioxidant is sodium metabisulfite;
和/或,所述脱色处理的温度为95-110℃,即煮沸即可;And/or, the temperature of the decolorization treatment is 95-110°C, that is, boiling;
和/或,所述脱色处理的时间为20-40min,优选为30min。And/or, the time for the decolorization treatment is 20-40 minutes, preferably 30 minutes.
在上述制备方法,作为一种优选实施方式,所述重结晶处理是将过滤处理后的滤液降温结晶,优选地,降温至25-30℃。In the above preparation method, as a preferred embodiment, the recrystallization treatment is to crystallize the filtrate after the filtration treatment by lowering the temperature, preferably lowering the temperature to 25-30°C.
第二方面,本发明还提供了一种上述制备方法得到的对乙酰氨基酚;In the second aspect, the present invention also provides acetaminophen obtained by the above preparation method;
在上述对乙酰氨基酚中,作为一种优选实施方式,所述对乙酰氨基酚中对乙酰氨基酚杂质H含量低于0.005%。In the above acetaminophen, as a preferred embodiment, the acetaminophen impurity H content in the acetaminophen is less than 0.005%.
发明人意外发现,调低粗品制备过程中加入的稀酸的浓度可以降低对乙酰氨基酚中对乙酰氨基酚杂质H的含量,同时对其他杂质的去除没有明显不利影响,且最终产品收率未降低。The inventor unexpectedly found that reducing the concentration of the dilute acid added in the crude product preparation process can reduce the content of acetaminophen impurity H in acetaminophen, and at the same time have no obvious adverse effects on the removal of other impurities, and the yield of the final product has not changed. reduce.
本发明与现有技术相比,具有如下有益效果:Compared with the prior art, the present invention has the following beneficial effects:
1、本发明方法可以将对乙酰氨基酚中的杂质H含量控制在0.005%以下,多批次生产的对乙酰氨基酚中杂质H含量控制稳定,产品合格率高。1. The method of the present invention can control the content of impurity H in the paracetamol below 0.005%, the content of impurity H in the paracetamol produced in multiple batches is controlled stably, and the qualified rate of the product is high.
2、本发明通过降低酰化母液(稀酸)中醋酸浓度来减少对乙酰氨基酚与冰醋酸的酯化反应,从而降低对乙酰氨基酚中杂质H含量,并且由于酰化母液醋酸浓度的降低,减少了醋酸单耗,节省了生产成本。另外,此工艺调整并未对其他杂质的去除和最终产品收率产生明显不利影响。2. The present invention reduces the esterification reaction of acetaminophen and glacial acetic acid by reducing the concentration of acetic acid in the acylation mother liquor (dilute acid), thereby reducing the content of impurity H in the acylation mother liquor, and due to the reduction of the concentration of acetic acid in the acylation mother liquor , reducing the unit consumption of acetic acid and saving production costs. In addition, this process adjustment did not have a significant adverse effect on the removal of other impurities and the yield of the final product.
3、对于本发明的优选技术方案,还可以进一步降低精品中对乙酰氨基酚杂质N的含量至0.005%以下。3. For the preferred technical solution of the present invention, the content of the paracetamol impurity N in the finished product can be further reduced to below 0.005%.
具体实施方式Detailed ways
下面将对本发明实施例中的技术方案进行清楚、完整地描述,以使本领域的技术人员能够实践和再现。基于本发明中的实施例,本领域普通技术人员所获得的所有其他实施例,都属于本发明保护的范围。The following will clearly and completely describe the technical solutions in the embodiments of the present invention, so that those skilled in the art can practice and reproduce them. All other embodiments obtained by persons of ordinary skill in the art based on the embodiments of the present invention belong to the protection scope of the present invention.
下面通过实施例对本发明一种控制对乙酰氨基酚杂质H含量的对乙酰氨基酚的制备方法进行进一步的详细描述,给出的实施例仅为了阐明本发明,而不是为了限制本发明的范围。以下提供的实施例可作为本技术领域普通技术人员进行进一步改进或应用的基础,并不以任何方式构成对本发明的具体限制。A method for preparing acetaminophen that controls the content of acetaminophen impurity H of the present invention will be further described in detail below through examples. The given examples are only to illustrate the present invention, rather than to limit the scope of the present invention. The examples provided below can be used as the basis for further improvement or application by those skilled in the art, and do not constitute a specific limitation to the present invention in any way.
以下实施例中未特别说明的百分比为质量百分比。The percentages not specified in the following examples are percentages by mass.
实施例1Example 1
对乙酰氨基酚粗品制备:将100g的对氨基苯酚(对氨基苯酚的含量为99.76%(HPLC),其中4,4'-二氨基二苯醚≤0.1%)、65g冰醋酸、0.8g焦亚硫酸钠及150g酰化母液(醋酸质量分数为40%)加入1000ml四口瓶中进行酰化反应,110℃反应3小时后,进行采酸处理,110℃采酸1h,后缓慢升温至135℃,采酸2h,采酸量为30g时,停止采酸,降温至25℃,离心得对乙酰氨基酚粗品139g。Preparation of paracetamol crude product: 100g of p-aminophenol (the content of p-aminophenol is 99.76% (HPLC), wherein 4,4'-diaminodiphenyl ether≤0.1%), 65g of glacial acetic acid, 0.8g of sodium metabisulfite and 150g of acylation mother liquor (the mass fraction of acetic acid is 40%) was added into a 1000ml four-neck bottle for acylation reaction, and after 3 hours of reaction at 110°C, acid mining was carried out. After 2 hours of acid extraction, when the amount of acid extraction was 30 g, the acid extraction was stopped, the temperature was lowered to 25° C., and 139 g of crude acetaminophen was obtained by centrifugation.
对乙酰氨基酚重结晶制备:将139g的对乙酰氨基酚粗品、210g纯化水、6.95g焦亚硫酸钠及2.78g活性炭加入1000ml四口瓶中进行重结晶反应,100℃脱色30min后,过滤炭,滤液缓慢降温至25℃,离心,干燥得精制对乙酰氨基酚成品128g,收率为92.4%。Preparation of paracetamol recrystallization: add 139g of crude paracetamol, 210g of purified water, 6.95g of sodium metabisulfite and 2.78g of activated carbon into a 1000ml four-neck flask for recrystallization reaction, decolorize at 100°C for 30min, filter carbon, and filtrate Slowly cool down to 25°C, centrifuge, and dry to obtain 128g of refined acetaminophen finished product, with a yield of 92.4%.
按照EP10标准检测精制对乙酰氨基酚产品中的各项杂质含量,各项杂质的具体含量参见表1。EP10标准中记载的杂质H和N的检测方法的最低报告限均为0.03%。According to the EP10 standard, the content of each impurity in the refined acetaminophen product is detected, and the specific content of each impurity is shown in Table 1. The minimum reporting limits of the detection methods for impurities H and N recorded in the EP10 standard are both 0.03%.
表1Table 1
其中,“其它单个未知杂质”是指除杂质J、K以外杂质中含量最大的单杂。Among them, "other single unknown impurity" refers to the single impurity with the largest content among impurities except impurity J and K.
采用该实施例的方法生产多批次对乙酰氨基酚,均未检测到杂质H。Using the method of this example to produce multiple batches of paracetamol, impurity H was not detected.
实施例2Example 2
对乙酰氨基酚粗品制备:将100g的对氨基苯酚(对氨基苯酚的含量为99.76%(HPLC),其中4,4'-二氨基二苯醚≤0.1%)、66g冰醋酸、0.6g焦亚硫酸钠及150g酰化母液(醋酸质量分数为42%)加入1000ml四口瓶中进行酰化反应,113℃反应3小时后,进行采酸处理,110℃采酸1h,后缓慢升温至135℃,采酸2h,采酸量为30g时,停止采酸,降温至25℃,离心得对乙酰氨基酚粗品135g。Preparation of paracetamol crude product: 100g of p-aminophenol (the content of p-aminophenol is 99.76% (HPLC), wherein 4,4'-diaminodiphenyl ether≤0.1%), 66g of glacial acetic acid, 0.6g of sodium metabisulfite And 150g of acylation mother liquor (the mass fraction of acetic acid is 42%) was added into a 1000ml four-necked bottle for acylation reaction, and after 3 hours of reaction at 113°C, acid mining was carried out, at 110°C for 1 hour, and then the temperature was slowly raised to 135°C. After 2 hours of acid extraction, when the amount of acid extraction was 30 g, the acid extraction was stopped, the temperature was lowered to 25° C., and 135 g of crude acetaminophen was obtained by centrifugation.
对乙酰氨基酚重结晶制备:将135g的对乙酰氨基酚粗品、210g纯化水、7.0g焦亚硫酸钠及2.9g活性炭加入1000ml四口瓶中进行重结晶反应,100℃脱色30min后,过滤炭,滤液缓慢降温至25℃,离心,干燥得精制对乙酰氨基酚成品129g,收率为93.1%。Preparation of paracetamol recrystallization: add 135g of crude paracetamol, 210g of purified water, 7.0g of sodium metabisulfite and 2.9g of activated carbon into a 1000ml four-necked bottle for recrystallization reaction, decolorize at 100°C for 30min, filter the charcoal, and filtrate Slowly lower the temperature to 25° C., centrifuge, and dry to obtain 129 g of refined paracetamol finished product, with a yield of 93.1%.
按照EP10标准检测精制对乙酰氨基酚产品中的各项杂质含量,各项杂质的具体含量参见表2。According to the EP10 standard, the content of each impurity in the refined acetaminophen product is detected, and the specific content of each impurity is shown in Table 2.
表2Table 2
其中,“其它单个未知杂质”是指除杂质J、K以外杂质中含量最大的单杂。Among them, "other single unknown impurity" refers to the single impurity with the largest content among impurities except impurity J and K.
实施例3Example 3
对乙酰氨基酚粗品制备:将100g的对氨基苯酚(对氨基苯酚的含量为99.79%(HPLC),其中4,4'-二氨基二苯醚≤0.1%)、66g冰醋酸、1.0g焦亚硫酸钠及150g酰化母液(醋酸质量分数为45%)加入1000ml四口瓶中进行酰化反应,105℃反应3小时后,进行采酸处理,110℃采酸1h,后缓慢升温至135℃,采酸2h,采酸量为30g时,停止采酸,降温至25℃,离心得对乙酰氨基酚粗品142g。Preparation of paracetamol crude product: 100g of p-aminophenol (the content of p-aminophenol is 99.79% (HPLC), wherein 4,4'-diaminodiphenyl ether≤0.1%), 66g of glacial acetic acid, 1.0g of sodium metabisulfite And 150g of acylation mother liquor (the mass fraction of acetic acid is 45%) was added into a 1000ml four-necked bottle for acylation reaction, after 3 hours of reaction at 105°C, acid mining was carried out, at 110°C for 1 hour, and then the temperature was slowly raised to 135°C. After 2 hours of acid extraction, when the amount of acid extraction was 30 g, the acid extraction was stopped, the temperature was lowered to 25° C., and 142 g of crude acetaminophen was obtained by centrifugation.
对乙酰氨基酚重结晶制备:将142g的对乙酰氨基酚粗品、210g纯化水、7.0g焦亚硫酸钠及3.0g活性炭加入1000ml四口瓶中进行重结晶反应,100℃脱色30min后,过滤炭,滤液缓慢降温至25℃,离心,干燥得精制对乙酰氨基酚成品128g,收率为92.4%。Preparation of paracetamol recrystallization: Add 142g of crude paracetamol, 210g of purified water, 7.0g of sodium metabisulfite and 3.0g of activated carbon into a 1000ml four-neck flask for recrystallization reaction, decolorize at 100°C for 30min, filter the charcoal, and filtrate Slowly lower the temperature to 25° C., centrifuge, and dry to obtain 128 g of refined acetaminophen finished product, with a yield of 92.4%.
按照EP10标准检测精制对乙酰氨基酚产品中的各项杂质含量,各项杂质的具体含量参见表3。According to the EP10 standard, the content of each impurity in the refined paracetamol product is detected, and the specific content of each impurity is shown in Table 3.
表3table 3
其中,“其它单个未知杂质”是指除杂质J、K以外杂质中含量最大的单杂。Among them, "other single unknown impurity" refers to the single impurity with the largest content among impurities except impurity J and K.
对比例1Comparative example 1
对乙酰氨基酚粗品制备:将100g的对氨基苯酚(对氨基苯酚的含量为99.76%(HPLC),其中4,4'-二氨基二苯醚≤0.1%)、65g冰醋酸、0.8g焦亚硫酸钠及150g酰化母液(醋酸质量分数为54%)加入1000ml四口瓶中进行酰化反应,110℃反应3小时后,进行采酸处理,110℃采酸1h,后缓慢升温至135℃,采酸2h,采酸量为30g时,停止采酸,降温至25℃,离心得对乙酰氨基酚粗品139g。Preparation of paracetamol crude product: 100g of p-aminophenol (the content of p-aminophenol is 99.76% (HPLC), wherein 4,4'-diaminodiphenyl ether≤0.1%), 65g of glacial acetic acid, 0.8g of sodium metabisulfite and 150g of acylation mother liquor (the mass fraction of acetic acid is 54%) was added into a 1000ml four-necked bottle for acylation reaction, and after 3 hours of reaction at 110°C, acid mining was carried out. After aciding for 2 hours, when the amount of acid collected was 30g, the acid collection was stopped, the temperature was lowered to 25°C, and 139g of crude paracetamol was obtained by centrifugation.
对乙酰氨基酚重结晶制备:将139g的对乙酰氨基酚、210g纯化水、6.95g焦亚硫酸钠及2.78g活性炭加入1000ml四口瓶中进行重结晶反应,100℃脱色30min后,过滤炭,滤液缓慢降温至25℃,离心,干燥得精制对乙酰氨基酚成品128g,收率为92.4%。Preparation of acetaminophen recrystallization: add 139g of acetaminophen, 210g of purified water, 6.95g of sodium metabisulfite and 2.78g of activated carbon into a 1000ml four-necked bottle for recrystallization reaction, decolorize at 100°C for 30min, filter carbon, and the filtrate slowly Cool down to 25°C, centrifuge, and dry to obtain 128 g of refined acetaminophen finished product, with a yield of 92.4%.
按照EP10标准检测精制对乙酰氨基酚产品中的各项杂质含量,各项杂质的具体含量参见表4。According to the EP10 standard, the content of each impurity in the refined paracetamol product is detected, and the specific content of each impurity is shown in Table 4.
表4Table 4
其中,“其它单个未知杂质”是指除杂质J、K以外杂质中含量最大的单杂。Among them, "other single unknown impurity" refers to the single impurity with the largest content among impurities except impurity J and K.
实施例4Example 4
本实施例与实施例1工艺的区别仅在于:对乙酰氨基酚粗品制备中酰化反应温度为95℃,其它工艺条件与实施例1相同。该实施例4的精制对乙酰氨基酚成品的收率92.5%。The difference between the process of this example and Example 1 is only that the acylation reaction temperature in the preparation of the crude paracetamol is 95° C., and other process conditions are the same as those of Example 1. The yield of the refined paracetamol finished product of this embodiment 4 is 92.5%.
按照EP10标准检测精制对乙酰氨基酚产品中的各项杂质含量,各项杂质的具体含量参见下表5。According to the EP10 standard, the content of various impurities in the refined paracetamol product is detected, and the specific content of each impurity is shown in Table 5 below.
表5table 5
其中,“其它单个未知杂质”是指除杂质J、K以外杂质中含量最大的单杂。Among them, "other single unknown impurity" refers to the single impurity with the largest content among impurities except impurity J and K.
实施例5Example 5
本实施例与实施例1工艺的区别仅在于:对乙酰氨基酚粗品制备中焦亚硫酸钠的用量为1.5g,其它工艺条件与实施例1相同。该实施例5的精制对乙酰氨基酚成品的收率92.4%。The difference between this embodiment and the process of Example 1 is only that the amount of sodium metabisulfite used in the preparation of the crude paracetamol is 1.5 g, and other process conditions are the same as in Example 1. The yield of the refined paracetamol finished product of this embodiment 5 is 92.4%.
按照EP10标准检测精制对乙酰氨基酚产品中的各项杂质含量,各项杂质的具体含量参见下表6。According to the EP10 standard, the content of each impurity in the refined acetaminophen product is detected, and the specific content of each impurity is shown in Table 6 below.
表6Table 6
其中,“其它单个未知杂质”是指除杂质J、K以外杂质中含量最大的单杂。Among them, "other single unknown impurity" refers to the single impurity with the largest content among impurities except impurity J and K.
实施例6Example 6
本实施例与实施例1工艺的区别仅在于:对乙酰氨基酚粗品制备中焦亚硫酸钠的用量为1.5g,对乙酰氨基酚粗品制备中酰化反应温度为95℃,其它工艺条件与实施例1相同。该实施例6的精制对乙酰氨基酚成品的收率92.7%。The difference between the process of this example and Example 1 is that the amount of sodium metabisulfite used in the preparation of the crude paracetamol is 1.5 g, the temperature of the acylation reaction in the preparation of the crude paracetamol is 95° C., and other process conditions are the same as in Example 1. same. The yield of the refined paracetamol finished product of this embodiment 6 is 92.7%.
按照EP10标准检测精制对乙酰氨基酚产品中的各项杂质含量,各项杂质的具体含量参见下表7。According to the EP10 standard, the content of each impurity in the refined acetaminophen product is detected, and the specific content of each impurity is shown in Table 7 below.
表7Table 7
其中,“其它单个未知杂质”是指除杂质J、K以外杂质中含量最大的单杂。Among them, "other single unknown impurity" refers to the single impurity with the largest content among impurities except impurity J and K.
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均在本发明待批权利要求保护范围之内。The above descriptions are only preferred embodiments of the present invention, and are not intended to limit the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention are within the scope of the pending rights of the present invention. within the scope of protection.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211497629.2A CN115894271A (en) | 2022-11-25 | 2022-11-25 | A kind of preparation method of the paracetamol that controls paracetamol impurity H content |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211497629.2A CN115894271A (en) | 2022-11-25 | 2022-11-25 | A kind of preparation method of the paracetamol that controls paracetamol impurity H content |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115894271A true CN115894271A (en) | 2023-04-04 |
Family
ID=86480165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211497629.2A Pending CN115894271A (en) | 2022-11-25 | 2022-11-25 | A kind of preparation method of the paracetamol that controls paracetamol impurity H content |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115894271A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105152956A (en) * | 2015-08-05 | 2015-12-16 | 安丘市鲁安药业有限责任公司 | Process and device for acylation reaction of acetaminophen |
| CN111170880A (en) * | 2020-01-06 | 2020-05-19 | 河北冀衡(集团)药业有限公司 | Production system and method of acetaminophen |
| CN114965754A (en) * | 2022-05-13 | 2022-08-30 | 陕西必康制药集团控股有限公司 | Method for detecting related substances and bacteriostatic agent in acetaminophen tablet |
-
2022
- 2022-11-25 CN CN202211497629.2A patent/CN115894271A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105152956A (en) * | 2015-08-05 | 2015-12-16 | 安丘市鲁安药业有限责任公司 | Process and device for acylation reaction of acetaminophen |
| CN111170880A (en) * | 2020-01-06 | 2020-05-19 | 河北冀衡(集团)药业有限公司 | Production system and method of acetaminophen |
| CN114965754A (en) * | 2022-05-13 | 2022-08-30 | 陕西必康制药集团控股有限公司 | Method for detecting related substances and bacteriostatic agent in acetaminophen tablet |
Non-Patent Citations (4)
| Title |
|---|
| FRANK ELLIS: "Paracetamol - a curriculum resource", 31 December 2002, 皇家化学学会出版, pages: 1 - 24 * |
| 彭银仙: "《化学工艺学》", 31 July 2018, 哈尔滨工程大学出版社, pages: 221 * |
| 王婧: "复方对乙酰氨基酚片(II)质量评价与标准研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》, 15 October 2022 (2022-10-15), pages 079 - 44 * |
| 薛金星 等: "《中学教材全解 高中化学 选修 有机化学基础》", 31 May 2005, 北京教育出版社, pages: 185 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6218574B1 (en) | Process for purifying long-chain dicarboxylic acid | |
| CN111574409A (en) | A kind of recrystallization process method of nafamostat mesylate | |
| CN106928306A (en) | A kind of purification process of urso | |
| CN109369431B (en) | A kind of crystallization method of γ-aminobutyric acid | |
| US6706710B2 (en) | Form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide | |
| WO2020207130A1 (en) | Process for separating and purifying artemisinin | |
| JPH01224388A (en) | Precipitation of bancomycin | |
| CN115894271A (en) | A kind of preparation method of the paracetamol that controls paracetamol impurity H content | |
| CN115872885B (en) | Preparation method of acetaminophen with controlled content of acetaminophen impurity N | |
| CN111732547B (en) | A kind of refining method and use of olaparib | |
| WO2021212535A1 (en) | Method for refining benzhexol hydrochloride | |
| CN113845423B (en) | Pharmaceutical auxiliary material sodium stearyl fumarate with uniform sheet-shaped structure and preparation method thereof | |
| CN103012535B (en) | Method for preparing refined cholesterol by separating cholesterol from egg oil | |
| CN115073444A (en) | Method for refining and removing lurasidone hydrochloride epoxy impurities | |
| CN116693594A (en) | Synthesis method and application of magnesium isoglycyrrhetate | |
| CN112851616A (en) | Semi-synthesis method of eriodictyol | |
| CN113004366A (en) | Novel method for producing diammonium glycyrrhizinate | |
| CN1219788C (en) | Dynamic controlled crystalline method of preparing erythromycin from erythromysin salt | |
| CN118388558B (en) | Anhydrous psicose crystal and preparation method thereof | |
| CN108948017B (en) | Purification method of folic acid | |
| CN110818816A (en) | Refining and crystallizing method of sugammadex sodium | |
| CN106432021B (en) | A kind of preparation method of Fudosteine crystallization | |
| CN115594640B (en) | A method for refining dibenzoyl thiamine disulfide | |
| CN114031611B (en) | A kind of preparation method of small particle size terazosin hydrochloride with low ethanol residue | |
| CN109456291A (en) | A kind of method of low temperature rapid crystallization production griseofulvin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230404 |